Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter

Cancer statistics, 2000

2000 • 3,907 citations

Prostate Specific Antigen: A Critical Assessment of the Most Useful Tumor Marker for Adenocarcinoma of the Prostate

1991 • 1,273 citations

Comparison of Digital Rectal Examination and Serum Prostate Specific Antigen in the Early Detection of Prostate Cancer: Results of a Multicenter Clinical Trial of 6,630 Men

1994 • 1,171 citations

A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer.

1991 • 954 citations

Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin

1991 • 947 citations

[Principles and practice of mass screening for disease].

1968 • 730 citations

Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria

2001 • 320 citations

Measurement of complexed PSA improves specificity for early detection of prostate cancer

1998 • 171 citations

COMPLEXED PROSTATE SPECIFIC ANTIGEN PROVIDES SIGNIFICANT ENHANCEMENT OF SPECIFICITY COMPARED WITH TOTAL PROSTATE SPECIFIC ANTIGEN FOR DETECTING PROSTATE CANCER

2000 • 149 citations

In vitro stability of free prostate-specific antigen (PSA) and prostate-specific antigen (PSA) complexed to α1-antichymotrypsin in blood samples

1996 • 136 citations

Prostate specific antigen predominantly forms a complex with alpha1-antichymotrypsin in blood. Implications for procedures to measure prostate specific antigen in serum

1992 • 107 citations

Prostate-specific antigen. Current role in diagnostic pathology of prostate cancer.

1994 • 73 citations

CAN COMPLEXED PROSTATE SPECIFIC ANTIGEN AND PROSTATIC VOLUME ENHANCE PROSTATE CANCER DETECTION IN MEN WITH TOTAL PROSTATE SPECIFIC ANTIGEN BETWEEN 2.5 AND 4.0 NG./ML.

2001 • 72 citations

Practice Trends in the Diagnosis and Management of Prostate Cancer in the United States

1995 • 62 citations

Improvement of specificity in PSA-based screening by using PSA-transition zone density and percent free PSA in addition to total PSA levels

1998 • 53 citations

Determination of alpha1-antichymotrypsin-PSA complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared with total PSA and percent free PSA

1999 • 41 citations

Molecular forms of prostate-specific antigen in serum with concentrations of total prostate-specific antigen <4 ?g/L: Are they useful tools for early detection and screening of prostate cancer?

2001 • 28 citations

Different Stability of Free and Complexed Prostate-Specific Antigen in Serum in Relation to Specimen Handling and Storage Conditions

2000 • 26 citations

Comparisons of the Various Combinations of Free, Complexed, and Total Prostate–Specific Antigen for the Detection of Prostate Cancer

2000 • 25 citations

Prostate-Specific Antigen and Its Complexes with AlpharAntichymotrypsin in the Plasma of Patients with Prostatic Disease

1996 • 21 citations

Consideration of Low PSA Cut-Off Levels to Optimize the Detection of Curable Prostate Cancer

2001 • 19 citations

Prostate Specific Antigen

1994 • 10 citations